Angel Porgador
Overview
Explore the profile of Angel Porgador including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
3940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
2.
Pandit J, Yassin A, Martin C, Saux G, Porgador A, Schvartzman M
Acta Biomater
. 2025 Feb;
195:83-93.
PMID: 39952341
T cells, key players in the immune system, recognize antigens via T-cell receptors (TCRs) and require additional costimulatory and cytokine signals for full activation. Beyond biochemical signals, T cells also...
3.
Novoplansky O, Jagadeeshan S, Prasad M, Yegodayev K, Marripati D, Shareb R, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):308.
PMID: 39567998
Background: Basket clinical trials targeting the KRAS-mutation in solid tumors have shown initial promise, including in orphan KRAS head and neck cancer (HNC). However, development of resistance to KRAS-mutant-specific inhibitors...
4.
5.
Bar O, Porgador A, Cooks T
J Extracell Biol
. 2024 Sep;
3(9):e70011.
PMID: 39328262
Cancer therapy is a dynamically evolving field, witnessing the emergence of innovative approaches that offer a promising outlook for patients grappling with persistent disease. Within the realm of therapeutic exploration,...
6.
Zismanov S, Shalem B, Margolin-Miller Y, Rosin-Grunewald D, Adar R, Keren-Naus A, et al.
Commun Med (Lond)
. 2024 Jun;
4(1):121.
PMID: 38898090
Background: The SARS-CoV-2 pandemic led to unprecedented testing demands, causing major testing delays globally. One strategy used for increasing testing capacity was pooled-testing, using a two-stage technique first introduced during...
7.
Kaufman B, Taha T, Abramov O, Zohar Y, Mhameed K, Cohen O, et al.
NPJ Precis Oncol
. 2024 Jun;
8(1):126.
PMID: 38830971
Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the...
8.
Pandey A, Nowakowski P, Martin C, Abu Ahmad M, Edri A, Toledo E, et al.
Nano Lett
. 2024 Apr;
24(18):5395-5402.
PMID: 38684070
We investigated the role of ligand clustering and density in the activation of natural killer (NK) cells. To that end, we designed reductionist arrays of nanopatterned ligands arranged with different...
9.
Fuchs V, Sobarzo A, Msamra M, Kezerle Y, Linde L, Sevillya G, et al.
Clin Transl Oncol
. 2024 Mar;
26(9):2227-2239.
PMID: 38553659
Purpose: In the pursuit of creating personalized and more effective treatment strategies for lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as preclinical platforms that can recapitulate the specific...
10.
Tzadka S, Martin C, Toledo E, Yassin A, Pandey A, Saux G, et al.
ACS Appl Mater Interfaces
. 2024 Mar;
16(14):17846-17856.
PMID: 38549366
We introduce a novel approach for colloidal lithography based on the dry particle assembly into a dense monolayer on an elastomer, followed by mechanical transfer to a substrate of any...